MétaCan
Menu
Back to cohort
Record W4311917936 · doi:10.1016/j.annonc.2022.12.004

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit

2022· article· en· W4311917936 on OpenAlexaff
Sjoukje F. Oosting, Jorge Barriuso, Andrew Bottomley, M. Galotti, Bishal Gyawali, Barbara Kiesewetter, N.J. Latino, Francesca Martinelli, Madeline Pe, G. Pentheroudakis, Felipe Roitberg, H. Vachon, Elisabeth G.E. de Vries, Martine Piccart, Nathan I. Cherny

Bibliographic record

VenueAnnals of Oncology · 2022
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicEconomic and Financial Impacts of Cancer
Canadian institutionsQueen's University
FundersGenentechIpsenEuropean Society for Medical OncologyChugai PharmaceuticalSeagenRegeneron PharmaceuticalsServierG1 TherapeuticsAmgenPfizerWorld Health OrganizationRadius HealthAstraZenecaEli Lilly and Company
KeywordsMedicineChecklistQuality of life (healthcare)Clinical trialClinical endpointScale (ratio)Test (biology)Medical physicsIntensive care medicineInternal medicineNursing

Abstract

fetched live from OpenAlex

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been developed to grade clinical benefit of cancer therapies. Improvement in quality of life (QoL) is considered relevant, especially in the non-curative setting. This is reflected by an upgrade of the preliminary ESMO-MCBS score if QoL is improved compared to the control arm or a downgrade if an improvement in progression-free survival is not paralleled by an improvement in QoL or overall survival. Given the importance of QoL for the final score, a need to ensure the robustness of QoL data was recognised. DESIGN: A checklist was created based on existing guidelines for QoL research. Field testing was carried out using clinical trials that either received an adjustment of the preliminary ESMO-MCBS score based on QoL or had QoL as the primary endpoint. Several rounds of revision and re-testing of the checklist were undertaken until a final consensus was reached. RESULTS: The final checklist consists of four items and can be applied if three prerequisites are met: (i) QoL is at least a secondary endpoint, (ii) evidence of reliability and validity of the instrument is provided, and (iii) a statistically and clinically significant improvement in QoL is observed. The four items on the checklist pertain to the (i) hypothesis, (ii) compliance and missing data, (iii) presentation of the results, and (iv) statistical and clinical relevance. Field testing revealed that a clear QoL hypothesis and correction for multiple testing were mostly lacking, while the main statistical method was always described. CONCLUSIONS: Implementation of the ESMO-MCBS QoL checklist will facilitate objective and transparent decision making on QoL data within the ESMO-MCBS scoring process. Trials published until 1 January 2025 will have to meet the prerequisites and at least two items for crediting QoL benefit in the final ESMO-MCBS score. Trials published thereafter will have to meet all four items.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.645
metaresearch head score (Gemma)0.830
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Reporting · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: none
Teacher disagreement score0.355
Threshold uncertainty score0.438

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.6450.830
Meta-epidemiology (narrow)0.0030.004
Meta-epidemiology (broad)0.0090.019
Bibliometrics0.0310.025
Science and technology studies0.0050.010
Scholarly communication0.0120.006
Open science0.0100.011
Research integrity0.0110.015
Insufficient payload (model declined to judge)0.0260.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.731
GPT teacher head0.575
Teacher spread0.157 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designNot applicable
DomainReporting
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations36
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of OncologySame topicEconomic and Financial Impacts of CancerFrench-language works237,207